<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The response of <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumours</z:e> to chemotherapy is highly variable </plain></SENT>
<SENT sid="1" pm="."><plain>Preclinical work has shown that the Kirsten ras (KRAS) oncogene sensitizes <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumour</z:e> cells to <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and <z:chebi fb="0" ids="31348">capecitabine</z:chebi> in a <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> suppressor p53 (TP53)-dependent manner </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, whether or not the combined mutation status of KRAS and TP53 could predict response to chemotherapy in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> was tested </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: A subgroup of patients from the CAIRO2 study (randomized phase III study on <z:chebi fb="0" ids="31348">capecitabine</z:chebi>, <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, bevacizumab with or without cetuximab in first-line advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>) that received <z:chebi fb="0" ids="31348">capecitabine</z:chebi> plus <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> (CAPOX) treatment in combination with bevacizumab was selected </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> were analyzed for KRAS and TP53 mutations by PCR/sequencing </plain></SENT>
<SENT sid="5" pm="."><plain>The relationship between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> response and genotype was analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The following KRAS/TP53 genotypes were identified: KRASmut/TP53mut n=21, KRASmut/TP53wt n=20, KRASwt/TP53mut n=25, KRASwt/TP53wt n=15 </plain></SENT>
<SENT sid="7" pm="."><plain>No genotype was associated with a significantly better or worse progression-free or overall survival </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: The combined mutation status of KRAS and TP53 does not predict response to CAPOX in patients with metastasized <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>